ArticleJournal of gynecologic oncology2010
The type of metastasis is a prognostic factor in disseminated cervical cancer.
Article in Journal of gynecologic oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic Role of Matrix Metalloproteinases in Cervical Cancer: A Meta-Analysis.Cancer control : journal of the Moffitt Cancer CenterPooled it
- Efficacy of radical doses of pelvic radiotherapy for primary tumor treatment in patients with newly diagnosed organ metastatic cervical cancer.Radiation oncology (London, England) · 2019Trial
- Mushroom-derived bioactive compounds pharmacological properties and cancer targeting: a holistic assessment.Discover oncology · 2025Review
- Review
- Risk and prognosis for brain metastasis in primary metastatic cervical cancer patients: A population-based study.Open medicine (Warsaw, Poland) · 2025Article
- Article
- A novel nomogram and risk stratification for early metastasis in cervical cancer after radical radiotherapy.Cancer medicine · 2023Article
- Outcomes associated with treatment to all sites of disease in patients with stage IVB cancer of the cervix.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2023Article
- TIM-1 promotes proliferation and metastasis, and inhibits apoptosis, in cervical cancer through the PI3K/AKT/p53 pathway.BMC cancer · 2022Article
- Dynamic Nomogram Based on the Metastatic Number and Sites and Therapy Strategies Predicting the Prognosis of Patients with Metastatic Cervical Cancer.International journal of women's health · 2022Article
- Survival, treatment pattern, and treatment outcome in patients with cervical cancer metastatic to distant lymph nodes.Frontiers in oncology · 2022Article
- Significance of Concurrent Chemoradiotherapy as Primary Treatment in Patients with Metastatic Cervical Cancer.Current oncology (Toronto, Ont.) · 2021Article
- Recurrent cervical cancer treated with palliative chemotherapy: real-world outcome.Ecancermedicalscience · 2020Article
- Surgery of primary sites for stage IVB cervical cancer patients receiving chemoradiotherapy: a population-based study.Journal of gynecologic oncology · 2020Article
- Clinicopathologic characteristics and survival analysis in stage IVB cervical cancer with hematogenous metastasis.Translational cancer research · 2019Article
- Simultaneous Metastasis from Cervical Cancer to the Kidney and Paraspinal Muscle: A Case Report.Cureus · 2019Article
- Impact of sites versus number of metastases on survival of patients with organ metastasis from newly diagnosed cervical cancer.Cancer management and research · 2019Article
- Race and nodal disease status are prognostic factors in patients with stage IVB cervical cancer.Oncotarget · 2018Article
- Cervical cancer metastasis to the brain: A case report and review of literature.Surgical neurology international · 2017Review
- Advances in diagnosis and treatment of metastatic cervical cancer.Journal of gynecologic oncology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTHE OBJECTIVES OF THIS STUDY WERE TWOFOLD: to verify whether the type of metastasis (lymphatic vs. hematogenous) is a prognostic factor, and to identify molecular markers associated with survival in patients with disseminated cervical cancer.
methodsBetween April 1997 and May 2008, 30 patients with disseminated cervical cancer who had supraclavicular lymph node (N=13) or hematogenous metastases (N=17) were initially treated at our institute. We reviewed medical records to extract clinicopathologic variables. For 17 patients with available pathological specimens, we evaluated the association of immunohistochemical staining for metalloproteinase (MMP)-2, vascular endothelial growth factor (VEGF)-A, and laminin V gamma (LAMC)-2 with survival and clinicopathologic variables via a log-rank test and Cox regression analysis.
resultsPatients who had only lymphatic metastasis (odds ratio [OR], 5.3; 95% confidence interval [CI], 1.4 to 19.5) or completed initial treatment (OR, 3.2; 95% CI, 1.1 to 9.9) showed better survival than patients who did not, but none of the molecular markers were associated with survival. Out of 13 patients with only lymphatic metastasis, three patients who had received volume-directed radiation with concurrent chemotherapy had a long-term survival of over two years. However, patients with hematogenous metastasis showed extremely poor prognosis.
conclusionThe type of metastasis and completion of initial treatment were associated with prolonged survival in patients with disseminated cervical cancer, and over 20% of patients with lymphatic metastasis were salvaged with volume-directed radiation with concurrent chemotherapy. None of the molecular markers were associated with survival in patients with disseminated cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.